AI Engines For more Details: Perplexity Kagi Labs You
Muscle Growth: Oxandrolone promotes protein synthesis in the body, leading to increased muscle mass and strength. It is used medically to help patients regain muscle mass lost due to prolonged illness or surgery.
Weight Gain: One of the primary medical uses of oxandrolone is to promote weight gain in patients who have experienced significant weight loss due to surgery, trauma, or chronic infections. It helps to increase lean body mass while minimizing the accumulation of fat tissue.
Bone Density: Oxandrolone has been shown to increase bone density, which can be beneficial for individuals at risk of osteoporosis or bone fractures, particularly postmenopausal women.
Treatment of Catabolic Conditions: It is used medically to counteract catabolic states (conditions where the body breaks down muscle tissue) associated with long-term corticosteroid therapy, chronic infections, or severe burns.
Anemia: Oxandrolone may be prescribed to treat anemia associated with bone marrow failure or certain chronic illnesses. It stimulates erythropoiesis (production of red blood cells) and can improve hemoglobin levels.
Wound Healing: In some cases, oxandrolone is used to promote wound healing and tissue repair in patients with severe burns or other traumatic injuries. It can aid in the regeneration of damaged tissues and accelerate the healing process.
Hormone Replacement Therapy: Oxandrolone is sometimes used as part of hormone replacement therapy in individuals with testosterone deficiency or delayed puberty. It can help stimulate puberty and promote the development of secondary sexual characteristics.
Improved Quality of Life: By promoting weight gain, muscle strength, and overall well-being, oxandrolone can improve the quality of life for individuals recovering from illness, injury, or surgical procedures.
Side Effects: Like other anabolic steroids, oxandrolone can cause side effects, including liver toxicity, cardiovascular complications (such as hypertension and changes in cholesterol levels), and psychiatric effects (such as mood swings, aggression, or depression).
Masculinizing Effects: In women, oxandrolone may cause masculinizing effects such as deepening of the voice, enlargement of the clitoris, and changes in menstrual cycles. These effects are dose-dependent and reversible upon discontinuation of the drug.
Children and Adolescents: Oxandrolone should be used with caution in children and adolescents, as it can interfere with growth and maturation if used for prolonged periods. It should only be prescribed under the supervision of a pediatric endocrinologist.
Abuse Potential: Due to its performance-enhancing effects, oxandrolone is sometimes abused by athletes and bodybuilders to improve muscle mass and strength. Misuse of the drug can lead to serious health consequences and is prohibited in competitive sports.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.5 | 0.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | -0.3 | |
| Allergies | 0.3 | 1 | -2.33 |
| Allergy to milk products | 0.7 | 0.7 | |
| Alzheimer's disease | 1 | 1 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.7 | 0.43 |
| Ankylosing spondylitis | 0.3 | 0.3 | |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.5 | 1.6 | -2.2 |
| Atherosclerosis | 1.3 | -1.3 | |
| Autism | 1.7 | 1.7 | 0 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Bipolar Disorder | 0.5 | -0.5 | |
| Brain Trauma | 0.5 | -0.5 | |
| Celiac Disease | 0.6 | 0.3 | 1 |
| Cerebral Palsy | 0.3 | 0.5 | -0.67 |
| Chronic Fatigue Syndrome | 0.1 | -0.1 | |
| Chronic Kidney Disease | 0.9 | -0.9 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | -0.5 | |
| Chronic Urticaria (Hives) | 0.7 | -0.7 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.5 | -0.5 | |
| Colorectal Cancer | 1.9 | 0.8 | 1.37 |
| Constipation | 0.1 | 0.5 | -4 |
| Coronary artery disease | 0.5 | -0.5 | |
| COVID-19 | 0.9 | 2.3 | -1.56 |
| Crohn's Disease | 1 | 1.6 | -0.6 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.3 | 0.5 | -0.67 |
| Depression | 1.7 | 2.6 | -0.53 |
| Endometriosis | 0.5 | -0.5 | |
| Epilepsy | 0.3 | 1 | -2.33 |
| Fibromyalgia | 0.6 | 0.6 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.5 | 0.2 |
| gallstone disease (gsd) | 0.9 | -0.9 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | |
| Generalized anxiety disorder | 0.3 | 0.3 | 0 |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.5 | -0.5 | |
| Gulf War Syndrome | 1 | -1 | |
| Hashimoto's thyroiditis | 0.9 | 0.3 | 2 |
| Heart Failure | 0.9 | -0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.7 | -0.7 | |
| hyperglycemia | 0.6 | 1 | -0.67 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1 | 0.9 | 0.11 |
| Hypothyroidism | 0.3 | 0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 0.6 | 2 | -2.33 |
| Insomnia | 1.6 | -1.6 | |
| Irritable Bowel Syndrome | 1.6 | 1.7 | -0.06 |
| ischemic stroke | 0.5 | -0.5 | |
| Liver Cirrhosis | 0.9 | 2.2 | -1.44 |
| Long COVID | 0.6 | 0.9 | -0.5 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.7 | -0.7 | |
| Menopause | 0.9 | -0.9 | |
| Metabolic Syndrome | 0.9 | 1.7 | -0.89 |
| Mood Disorders | 2.2 | 1.6 | 0.38 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.2 | 0.5 | 1.4 |
| Multiple system atrophy (MSA) | 1 | 1 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.9 | -0.9 | |
| Neuropathy (all types) | 0.3 | 0.5 | -0.67 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.6 | -1.67 |
| NonCeliac Gluten Sensitivity | 0.7 | 0.7 | |
| Obesity | 2.2 | 2.2 | 0 |
| obsessive-compulsive disorder | 0.1 | 0.7 | -6 |
| Osteoarthritis | 0.1 | 0.3 | -2 |
| Osteoporosis | 0.5 | 0.7 | -0.4 |
| Parkinson's Disease | 2.2 | 1.1 | 1 |
| Polycystic ovary syndrome | 0.7 | 0.9 | -0.29 |
| Psoriasis | 0.3 | 1.2 | -3 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.5 | 0.8 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.7 | 0.9 | -0.29 |
| Sleep Apnea | 0.5 | -0.5 | |
| Stress / posttraumatic stress disorder | 0.9 | 1.2 | -0.33 |
| Systemic Lupus Erythematosus | 0.5 | -0.5 | |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.8 | 0.7 | 0.14 |
| Type 2 Diabetes | 1.3 | 1.7 | -0.31 |
| Ulcerative colitis | 0.2 | 1.7 | -7.5 |
| Unhealthy Ageing | 0.1 | 0.9 | -8 |
| Vitiligo | 0.3 | -0.3 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
